Figures & data
Table 1. Characteristic of study group.
Figure 1. (A) Comparison of total anti-SARS-CoV-2 antibodies level in the groups of workers with and without a history of COVID19 previously vaccinated with a 2-dose and 3-dose series of BNT162b2. The data are presented as median (interquartile range). (B) Comparison of total anti-SARS-CoV-2 antibodies level in the groups of women and men with a history of COVID19 previously vaccinated with a 2-dose and 3-dose series of BNT162b2. The data are presented as median (interquartile range). (C) Comparison of total anti-SARS-CoV-2 antibodies level in the groups of workers before and after the age of 50 with a history of COVID19 previously vaccinated with a 2-dose and 3-dose series of BNT162b2. The data are presented as median (interquartile range). (D) Comparison of total anti-SARS-CoV-2 antibodies level in the group of workers with normal and increased BMI with a history of COVID19 previously vaccinated with a 2-dose and 3-dose series of BNT162b2. The data are presented as median (interquartile range). (E) Comparison of total anti-SARS-CoV-2 antibodies level in the groups of workers with and without coexisting diseases with a history of COVID19 previously vaccinated with a 2-dose and 3-dose series of BNT162b2. The data are presented as median (interquartile range). (F) Comparison of total anti-SARS-CoV-2 antibodies level in the groups of medical and non-medical workers with a history of COVID19 previously vaccinated with a 2-dose and 3-dose series of BNT162b2. The data are presented as median (interquartile range).
Figure 2. (A) Comparison of total anti-SARS-CoV-2 antibodies level in the groups of women and men without a history of COVID19 previously vaccinated with a 2-dose and 3-dose series of BNT162b2. The data are presented as median (interquartile range). (B) Comparison of total anti-SARS-CoV-2 antibodies level in the groups of patients before and after the age of 50 without a history of COVID19 previously vaccinated with a 2-dose and 3-dose series of BNT162b2. The data are presented as median (interquartile range). (C) Comparison of total anti-SARS-CoV-2 anti-bodies level in the group of patients with normal and increased BMI without a history of COVID19 previously vaccinated with a 2-dose and 3-dose series of BNT162b2. The data are presented as median (interquartile range). (D) Comparison of total anti-SARS-CoV-2 antibodies level in the groups of patients with and without coexisting diseases without a history of COVID19 previously vaccinated with a 2-dose and 3-dose series of BNT162b2. The data are presented as median (interquartile range). The data are presented as median (interquartile range). (E) Comparison of total anti-SARS-CoV-2 antibodies level in the groups of medical and non-medical workers without a history of COVID19 previously vaccinated with a 2-dose and 3-dose series of BNT162b2. The data are presented as median (interquartile range).
Figure 3. (A) Comparison of total anti-SARS-CoV-2 antibodies level between group of women and men without and with a history of COVID-19 after having a third dose of vaccine. The data are presented as median (interquartile range). (B) Comparison of total anti-SARS-CoV-2 antibodies level between groups of patients before and after the age of 50 without and with a history of COVID-19 after having a third dose of vaccine. The data are presented as median (interquartile range). (C) Comparison of total anti-SARS-CoV-2 antibodies level in the group of workers with normal and increased BMI without and with a history of COVID19 after having a third dose of vaccine. The data are presented as median (interquartile range). (D) Comparison of total anti-SARS-CoV-2 antibodies level in the groups of workers with and without coexisting diseases without and with a history of COVID19 after having a third dose of vaccine. The data are presented as median (interquartile range). The data are presented as median (interquartile range). (E) Comparison of total anti-SARS-CoV-2 antibodies level in the groups of medical and non-medical workers without and with a history of COVID19 after having a third dose of vaccine. The data are presented as median (interquartile range).
iann_a_2182907_sm5180.pdf
Download PDF (188 KB)Data availability statement
The full data presented in this study are available on request from the corresponding author.